Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad461 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Linlin Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medi…. Hauptthemen laut MEDLINE: Insulin Resistance, Diabetes Mellitus, Autoimmune Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Context
Type B insulin resistance syndrome (TBIRS) is a rare condition, for which effective treatment remains challenging.
Objective
This work aimed to summarize the clinical characteristics of TBIRS and explore effective therapeutic strategies.
Methods
The clinical manifestations, biochemical indices, and treatment of 8 patients (3 men and 5 women) with TBIRS from Peking Union Medical College Hospital were retrospectively analyzed and their clinical outcomes were evaluated.
Results
The average age of the patients was 49.5 ± 16.5 years, and the duration of the disease ranged from 2 months to 1 year. Seven patients with hyperglycemia had normal/lower triglycerides (TGs) and lower insulin-like growth factor 1 (IGF-1) levels. One patient complained of intractable hypoglycemia. Five patients had accompanied systemic lupus erythematosus, 2 had mixed connective tissue disease, and 1 had undifferentiated connective tissue disease. Five patients had acanthosis nigricans and 3 women of child-bearing age had hyperandrogenism. All 8 patients were treated with glucocorticoids combined with immunosuppressants, among whom, 5 received high-dose glucocorticoid pulse therapy followed by conventional-dose glucocorticoid therapy, all of whom achieved partial remission within 2 to 4 weeks. Among the 3 patients receiving conventional glucocorticoid therapy, 2 achieved partial remission within 2 to 4 weeks. Six patients were tracked for 10 weeks to 4 years; 4 and 2 achieved complete and partial remission, respectively.
Conclusion
Decreased serum complement 3 and IGF-1 levels and normal/decreased TG levels act as striking biochemical features of TBIRS. High-dose glucocorticoid pulse therapy followed by conventional-dose long-term therapy combined with immunosuppressants achieves good clinical efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Endocrinology of National Health Commis…
- Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, 450052, Henan Province, China.
- Department of Endocrinology, Benxi Central Hospital, Benxi City, 117000, Liaoning Province, China.
ORCID-Profile: Linlin Zhao, Wei Li, Hongbo Yang, Yuxiu Li
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Zhao, L., Li, W., Liu, L., Duan, L., Wang, L., Yang, H., Zhang, H., & Li, Y. (2023). Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad461
Vancouver
Zhao L, Li W, Liu L, Duan L, Wang L, Yang H, et al. Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad461
BibTeX
@article{Zhao2023,
author = {Zhao, Linlin and Li, Wei and Liu, Lv and Duan, Lian and Wang, Linjie and Yang, Hongbo and Zhang, Huabing and Li, Yuxiu},
title = {Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad461}
}
EUVIMED